About this trial
The Trendelenburg sign is a common clinical finding indicating hip abductor dysfunction and altered pelvic stability. The relationship between the Trendelenburg sign, spinopelvic biomechanics, hip muscle strength, and lumbar magnetic resonance imaging (MRI) abnormalities remains insufficiently understood. This study aims to investigate the association between Trendelenburg sign positivity and lumbar MRI findings, including facet arthropathy, ligamentum flavum hypertrophy, multifidus muscle morphology, and psoas muscle characteristics, as well as spinopelvic biomechanical parameters and hip abductor muscle strength.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 and 65 years.
Patients who have previously presented to the clinic with a complaint of low back pain.
Willingness and ability to provide written informed consent for participation in the study.
Availability of lumbar MRI images obtained within the previous 12 months and accessible for evaluation.
Disqualifiers
Presence of red flag conditions associated with low back pain, including malignancy, infection, acute trauma, or significant neurological deficits.
History of lumbar spine surgery.
Structural spinal anomalies such as sacralization or lumbarization.
Spinal deformities, including scoliosis.
Trial population
Adults aged 18-65 years with low back pain and available lumbar MRI scans obtained within the previous 12 months. Participants will undergo clinical assessment for Trendelenburg sign and hip function, and lumbar MRI evaluation for degenerative changes.
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Presence and Severity of Lumbar Facet Joint Arthropathy
Assessment of the presence and severity of lumbar facet joint arthropathy on magnetic resonance imaging (MRI) and its association with Trendelenburg sign positivity.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: